Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
ConditionSeminoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorGustave Roussy, Cancer Campus, Grand Paris
About this trial
The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18F-fluoro-désoxyglucose positron emission tomography (PET-TDM) in grade I (cohort 1) or metastatic (cohort 2) seminoma
Eligibility criteria
Qualifiers
Histologically proved seminoma after orchiectomy
Primary testicular or retroperitoneal
Normal alpha-fetoprotein before and after orchiectomy
No prior treatment with radiotherapy or chemotherapy
Disqualifiers
Patient infected by HIV, Hepatitis B or C
History, within 5 years, of cancer other than seminoma, except for treated skin cancer (Basal Cell) .
visceral metastasis
cerebral metastasis
Trial design
Treatments tested in this trial
- Carboplatin
- Etoposide
- Cisplatin
Treatment groups
271 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov